文献速递头颈部肿瘤放疗

局部晚期头颈癌超分割放疗随机试验长期随访:竞争性死亡下仍见持久治疗获益

Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-01-28

该随机试验自1988至1995年纳入331例III-IV期喉/咽癌患者,比较超分割放疗(HF,58 Gy/40次,每日两次)与常规放疗(CF,51 Gy/20次,每日一次)。中位随访13.6年,HF组5年总生存提高10%(40% vs 30%,p=0.04),10年获益缩小至3%(21% vs 18%);局部区域控制趋势更优(10年49% vs 39%,p=0.05),晚期≥3级毒性相似。

要点

  • HF组5年OS提高10%(40% vs 30%,p=0.04),10年缩小至3%(21% vs 18%)。
  • HF组局部区域控制10年趋势更优(49% vs 39%,p=0.05)。
  • 晚期≥3级毒性两组相似(10年11% vs 14%,p=0.27)。

核心结论

  • HF增加总剂量对局部区域控制有持久约10%的效果,且晚期毒性相当。
  • OS获益在5年明显(10%),但长期随访中相对死亡风险模式发生变化。

研究设计与样本

  • 随机对照试验,1988至1995年纳入331例III-IV期喉/咽癌患者。
  • 随机分为HF组(58 Gy/40次,每日两次)或CF组(51 Gy/20次,每日一次)。
  • 中位随访13.6年。

主要发现

  • 5年OS:HF 40% vs CF 30%(p=0.04);10年OS:21% vs 18%。
  • 5年LRC:HF 49% vs CF 40%;10年LRC:49% vs 39%(p=0.05)。
  • 5年DC:87% vs 85%;10年DC:87% vs 84%(p=0.56)。
  • 5年≥3级LT:9% vs 12%;10年LT:11% vs 14%(p=0.27)。
  • 多变量分析:HF降低死亡风险31%[HR 0.69(0.55-0.88),p<0.01],降低局部区域失败风险35%[HR 0.65(0.48-0.89),p<0.01]。

关键数值与推荐

  • HF方案:58 Gy/40次,每日两次;CF方案:51 Gy/20次,每日一次。
  • 原发癌死亡5年:HF 46% vs CF 51%;10年:49% vs 55%。
  • 竞争性死亡(多为吸烟相关)5年:HF 14% vs CF 19%;10年:30% vs 28%。

临床怎么用

  • 对局部晚期喉/咽癌,HF增加总剂量可带来持久的局部区域控制获益且不增加晚期毒性。
  • 长期随访中OS获益缩小,提示需关注竞争性死亡对生存终点的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: To examine the therapeutic ratio and mortality profile over time in a radiotherapy randomized trial in stage III-IV larynx/pharynx cancer with long-term follow-up. MATERIALS/METHODS: From 1988 to 1995, 331 cases were randomized to either hyperfractionated (HF) (58 Gy/40 fractions, twice daily) or conventional (CF) (51 Gy/20 fractions, once daily) radiotherapy. Overall survival (OS), locoregional (LRC), distant control (DC), ≥Grade 3 late toxicity (LT), and relative mortality risk profile over time were compared between both arms. RESULTS: Median follow-up was 13.6 years. HF had a 10% improved OS at 5-years (40% vs 30%, p = 0.04), but the benefit diminished to 3% at 10-years (21% vs 18%). A trend towards higher LRC with HF remained (5-year: 49% vs 40%; 10-year: 49% vs 39%, p = 0.05). DC rates were unchanged (5-year: 87% vs 85%; 10-year: 87 vs 84%, p = 0.56). LT rates were similar (HF vs CF: 5-year: 9% vs 12%; 10-year: 11% vs 14%, p = 0.27). Multivariable analysis confirmed that HF reduced mortality risk by 31% [HR 0.69 (0.55-0.88), p < 0.01] and locoregional failure risk by 35% [HR 0.65 (0.48-0.89), p < 0.01]. Index cancer mortality (5-year: 46% vs 51%; 10-year: 49% vs 55%) was lower in the HF arm. Competing mortality (mostly smoking-related) was also numerically lower with HF at 5-years (14% vs 19%) but became similar at 10-years (30% vs 28%). CONCLUSIONS: This trial confirms that HF with augmented total dose has a durable 10% effect size on LRC with comparable LT. OS benefit is evident at 5-years (10%) but relative mortality risk profile changes in longer follow-up.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. O'Sullivan B, Hui Huang S, Keane T, et al. Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. Clin Transl Radiat Oncol. 2020. PMID: 32055717. doi:10.1016/j.ctro.2020.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。